Therapeutic drug monitoring (TDM) has emerged as a strategy for treatment optimization in
inflammatory bowel diseases to maximize benefit and to reach more stringent, objective end …

Abstract Background and Aims We sought to analyze whether response to a second-line
biologic varies depending on the reason for discontinuation of the primary anti-TNF agent …

Objective We aimed to provide an evidence-supported update of the ECCO-ESPGHAN
guideline on the medical management of paediatric Crohn's disease [CD]. Methods We …

Abstract Background and Aims To report results from VISIBLE 2, a randomised, double-
blind, placebo-controlled, phase 3 trial evaluating a new subcutaneous [SC] vedolizumab …

Intestinal immune cell trafficking has been identified as a central event in the pathogenesis
of inflammatory bowel diseases (IBD). Intensive research on different aspects of the immune …

Background & Aims Vedolizumab is effective and safe for the treatment of Crohn's disease
(CD) and ulcerative colitis (UC). Little is known about the incidence rate of loss of response …

Background & Aims Trough concentrations of vedolizumab were found to correlate with
clinical response in phase 3 studies of patients with ulcerative colitis (UC) or Crohn's …

Vedolizumab is a humanized anti-α 4 β 7 integrin monoclonal antibody that selectively
blocks trafficking of memory T cells to inflamed gut tissue by inhibiting the α 4 β 7-mucosal …

Proposed treatment targets for the management of inflammatory bowel disease (IBD) have
moved beyond symptomatic improvement towards more objective end points, such as …

Background Increased knowledge of pathways involved in the pathogenesis of IBD has led
to the development of new treatment options for Crohn's disease (CD) and ulcerative colitis …